demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
anti-inflammatory therapies
anti GM-CSF
mavrilimumab MASH-COVID ...
clarithromycine Rashad ...
colchicine GRECCO-19 Lopes MIF Horby COLCOVID Salehzadeh RECOVERY ... COL-COVID ... COLCHIVID
Colchicine plus rosuvastatin COLSTAT Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs Guzman-Esquivel
Indomethacin Ravichandran
stem cells Carmenate ... Lanzoni Shu Shi
vilobelimab (IFX-1) PANAMO

9 studies excluded by filtering options 1

5423 Jeong, 2020 1150not a RCTrisk of bias not avaialble
5510 Malgorzata, 2020 1134not a RCThigh risk of bias
5555 Scarsi, 2020 1130not a RCTrisk of bias not avaialble
6188 Bruce, 2020 1100not a RCTrisk of bias not avaialble
6691 Tsiakos, 2020 1313not a RCThigh risk of bias
6960 Imam, 2020 1130not a RCTrisk of bias not avaialble
7011 Drake, 2021 1100not a RCTrisk of bias not avaialble
9868 Brunetti, 2020 1110not a RCTrisk of bias not avaialble
9869 Sandhu, 2020 1100not a RCTrisk of bias not avaialble